StockData
Immatics N.V. logo

Immatics N.V. (IMTX) stock

IMTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 1/30
$6.10−0.19 (-3.02%)

Close on Nov 18, 2026Market cap $817.84MP/E –Yield –

Immatics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -€182.02M. The highest annual figure on record is €29.95M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€182.02M–
FY2024Dec 31, 2024-€38.62M–
FY2023Dec 31, 2023-€101.73M-439.6%
FY2022Dec 31, 2022€29.95M–
FY2021Dec 31, 2021-€86.29M–
FY2020Dec 31, 2020-€69.72M–
FY2019Dec 31, 2019-€33.01M–
FY2018Dec 31, 2018-€34.41M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-€67.20M–
Q2 FY2025Jun 30, 2025-€53.13M–
Q2 FY2024Jun 30, 2024-€26.56M–
Q2 FY2023Jun 30, 2023-€14.32M–
Q2 FY2022Jun 30, 2022-€16.66M–
Q2 FY2021Jun 30, 2021-€23.40M–
Q2 FY2020Jun 30, 2020-€19.60M–

More Immatics figures

See a number that looks wrong?